Influenza and the patient with end-stage renal disease
Influenza is a commonly encountered and serious pathogen. Patients with end-stage renal disease are more susceptible to serious morbidity and mortality associated with influenza infection. Proper management of patients includes: vaccination, monitoring for symptoms and isolation of potentially infected patients as well as appropriate antiviral therapies. In some cases of exposure, chemoprophylaxis is warranted. Vaccination and appropriate therapies are associated with improved outcomes.
KeywordsInfluenza Vaccination End-stage renal disease Chemoprophylaxis
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
Human and animal rights
The articles does not contain any studies with any human participants performed by any of the authors.
For this type of study, formal consent is not required.
- 1.Thompson MG et al (2010) Estimates of deaths associated with seasonal influenza—United States 1976–2007. MMWR 59:1057–1062Google Scholar
- 2.World Health Organization (2009) Pandemic influenza preparedness and response: a WHO guidance document. WHO, GenevaGoogle Scholar
- 4.Treanor J (2015) In: Bennett JE (ed) Influenza principles and practice of infectious diseases, 8th edn. Elsevier, PhiladelphiaGoogle Scholar
- 5.De Clerq E (2007) Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends Pharm Sci 28(6):280–285Google Scholar
- 6.Cohen YZ, Dolin R (2015) Influenza. In: Kasper D et al (eds) Harrison’s principles of internal medicine, 19th Edn. McGraw-Hill Education, USAGoogle Scholar
- 8.York I, Donis RO (2012) The 2009 pandemic influenza virus: where did it come from, where is it now, and where is it going? CRRN Top Mirc Immun 370:241–257Google Scholar
- 10.United States Renal Data System (2016) 2016 USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, BethesdaGoogle Scholar
- 13.Hauser AB et al (2007) Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int 28(Supplement 3):S183–S187Google Scholar
- 18.Antonen JA et al (2003) Influenza vaccination of dialysis patients: cross-reactivity of induced haemagglutination-inhibiting antibodies to H3N2 subtype antigenic variants is comparable with the response of naturally infected young healthy adults. Nephrol Dial Transplant 18:777–781CrossRefPubMedGoogle Scholar
- 20.Peer Kidney Care Initiative. Peer Report: Dialysis Care and Outcomes in the United States, 2016. http://www.peerkidney.org/wp-content/uploads/2016/11/Chapter-2-Hospitalizations.pdf. Accessed 9 Feb 2017
- 32.Peer Kidney Care Initiative (2015) Seasonality of hospitalization for pneumonia, influenza, and dialysis access infection. AJKD 65:A67Google Scholar
- 34.ACIP (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza. MMWR 60(1):1–24Google Scholar
- 41.Rapivab Highlights of Prescribing Information. Rapivab.com. http://labeling.cslbehring.com/PI/US/Rapivab/EN/Rapivab-Prescribing-Information.pdf. Accessed 9 Feb 2017
- 42.Questions and Answers for Health Care Providers: Renal Dosing and Administration Recommendations for Peramivir IV. FDA.gov. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM190601.pdf. Accessed 9 Feb 2017